QSAM Biosciences organizacji Beta

Jaka jest wartość Beta organizacji QSAM Biosciences?

Wartość Beta organizacji QSAM Biosciences, Inc. to 2.35

Jaka jest definicja Beta?



BETA wskazuje, czy akcje są bardziej lub mniej zmienne niż rynek jako całość. Beta mniejsza niż 1 wskazuje, że akcje są mniej zmienne niż rynek, a beta więcej niż 1 wskazuje, że akcje są bardziej niestabilne. Zmienność jest mierzona jako fluktuacja ceny wokół średniej.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta firm w Health Care sektor na OTC w porównaniu do QSAM Biosciences

Czym się zajmuję organizacja QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Firmy z beta podobne do QSAM Biosciences